These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37660471)

  • 1. Transarterial chemoembolization plus lenvatinib with or without a PD-1 inhibitor for advanced and metastatic intrahepatic cholangiocarcinoma: a retrospective real-world study.
    Ning Z; Xie L; Yan X; Hua Y; Shi W; Lin J; Xu L; Meng Z
    Br J Radiol; 2023 Oct; 96(1150):20230079. PubMed ID: 37660471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy.
    Kuhlmann JB; Euringer W; Spangenberg HC; Breidert M; Blum HE; Harder J; Fischer R
    Eur J Gastroenterol Hepatol; 2012 Apr; 24(4):437-43. PubMed ID: 22261548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization Combining Immune Checkpoint Inhibitors in Unresectable Intrahepatic Cholangiocarcinoma: A Propensity Score Matching Analysis.
    Yang XG; Sun YY; Li DS; Xu GH; Huang XQ
    Front Immunol; 2022; 13():940009. PubMed ID: 35874708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of transarterial chemoembolization plus lenvatinib combined with PD-1 inhibitors versus transarterial chemoembolization plus lenvatinib for unresectable hepatocellular carcinoma: a meta-analysis.
    Chen Y; Jia L; Li Y; Cui W; Wang J; Zhang C; Bian C; Luo T
    Front Immunol; 2024; 15():1466113. PubMed ID: 39281676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of PD-1 inhibitors on prognosis in unresectable hepatocellular carcinoma treated with TACE and lenvatinib: a retrospective study.
    Ding Z; Fang G; Tang Y; Zeng Y
    Sci Rep; 2024 Jun; 14(1):14334. PubMed ID: 38906915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study.
    Cai M; Huang W; Huang J; Shi W; Guo Y; Liang L; Zhou J; Lin L; Cao B; Chen Y; Zhou J; Zhu K
    Front Immunol; 2022; 13():848387. PubMed ID: 35300325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study.
    Zhu C; Li H; Yang X; Wang S; Wang Y; Zhang N; Wang Y; Xue J; Zhang L; Ning C; Yang X; Xun Z; Chao J; Long J; Sang X; Zhu Z; Zhao H
    Cancer Immunol Immunother; 2023 Sep; 72(9):2949-2960. PubMed ID: 37247023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic chemotherapy plus transarterial chemoembolization versus systemic chemotherapy alone for unresectable intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study.
    Jiang N; Zhang Z; Yin X; Qiu H; Yan W; Hao Y; Yang W; Li H; Xu A; Mu K
    Radiol Med; 2024 Apr; 129(4):631-642. PubMed ID: 38355907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison analysis of PD-1/PD-L1 inhibitors plus lenvatinib or gemcitabine/cisplatin as first-line treatment for patients with advanced intrahepatic cholangiocarcinoma.
    Huang JX; Liu B; Li Y; Li X; Ding LJ; Wang NY
    Front Oncol; 2023; 13():1204486. PubMed ID: 37664019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy of lenvatinib, trans-arterial chemoembolization, and PD-1/L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and network meta-analysis.
    Liang Y; Gan L; Zeng D; Lin L; Xiong Z; Liao F; Wang A
    Clin Transl Oncol; 2024 Oct; 26(10):2652-2664. PubMed ID: 38671328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation and efficacy of TACE combined with lenvatinib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features.
    Zou X; Xu Q; You R; Yin G
    Cancer Med; 2023 May; 12(10):11315-11333. PubMed ID: 36951443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without transarterial chemoembolization in unresectable hepatocellular carcinoma.
    Xin Y; Zhang X; Liu N; Peng G; Huang X; Cao X; Zhou X; Li X
    Hepatol Int; 2023 Jun; 17(3):753-764. PubMed ID: 37038024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of postoperative adjuvant transarterial chemoembolization on the prognosis of early-stage intrahepatic cholangiocarcinoma: a single center study.
    Liu G; Guo W; Wang H; Liu W; Lei L; Xie Q; Li X; Zou S; Wang P; Zhou H; Hu H
    Ann Palliat Med; 2021 Apr; 10(4):3673-3683. PubMed ID: 33691434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenvatinib Plus Programmed Cell Death Protein-1 Inhibitor Beyond First-Line Systemic Therapy in Refractory Advanced Biliary Tract Cancer: A Real-World Retrospective Study in China.
    Shi C; Li Y; Yang C; Qiao L; Tang L; Zheng Y; Chen X; Qian Y; Yang J; Wu D; Xie F
    Front Immunol; 2022; 13():946861. PubMed ID: 35967452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transarterial Chemoembolization Combined With PD-1 Inhibitors Plus Lenvatinib Showed Improved Efficacy for Treatment of Unresectable Hepatocellular Carcinoma Compared With PD-1 Inhibitors Plus Lenvatinib.
    Wang J; Zhao M; Han G; Han X; Shi J; Mi L; Li N; Yin X; Duan X; Hou J; Yin F
    Technol Cancer Res Treat; 2023; 22():15330338231166765. PubMed ID: 37161343
    [No Abstract]   [Full Text] [Related]  

  • 16. Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis.
    Zhao S; Zhou M; Wang P; Yang J; Zhang D; Yin F; Song P
    Technol Cancer Res Treat; 2022; 21():15330338221133640. PubMed ID: 36259214
    [No Abstract]   [Full Text] [Related]  

  • 17. Adjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: a propensity score matching analysis.
    Liu WR; Tian MX; Tao CY; Tang Z; Zhou YF; Song SS; Jiang XF; Wang H; Zhou PY; Qu WF; Fang Y; Ding ZB; Zhou J; Fan J; Shi YH
    BMC Cancer; 2020 Jul; 20(1):642. PubMed ID: 32650743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic nomogram model for selecting between transarterial chemoembolization plus lenvatinib, with and without PD-1 inhibitor in unresectable hepatocellular carcinoma.
    Sheng Y; Wang Q; Liu H; Wang Q; Chen W; Xing W
    Br J Radiol; 2024 Feb; 97(1155):668-679. PubMed ID: 38303541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic arterial infusion chemotherapy plus lenvatinib with or without programmed cell death protein-1 inhibitors for advanced cholangiocarcinoma.
    Wei Z; Wang Y; Wu B; Liu Y; Wang Y; Ren Z; Yang X; Chen Q; Zhang Y
    Front Immunol; 2023; 14():1235724. PubMed ID: 37720223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Locoregional options in the management of cholangiocarcinoma: single center experience.
    Baydoun H; Meirovich H; Maroun G; Coburn N; David E
    Ann Palliat Med; 2021 Feb; 10(2):1784-1791. PubMed ID: 33725764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.